Cyclerion Therapeutics, Inc. (CYCN) — SEC Filings
Cyclerion Therapeutics, Inc. (CYCN) — 24 SEC filings. Latest: 8-K (Dec 1, 2025). Includes 9 8-K, 5 10-Q, 5 SC 13G/A.
View Cyclerion Therapeutics, Inc. on SEC EDGAR
Overview
Cyclerion Therapeutics, Inc. (CYCN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 1, 2025: Cyclerion Therapeutics, Inc. filed an 8-K on December 1, 2025, reporting an event under 'Other Events'. The filing does not contain specific financial transactions or material business updates beyond the standard reporting requirement.
Sentiment Summary
Across 24 filings, the sentiment breakdown is: 2 bearish, 22 neutral. The dominant filing sentiment for Cyclerion Therapeutics, Inc. is neutral.
Filing Type Overview
Cyclerion Therapeutics, Inc. (CYCN) has filed 9 8-K, 1 10-K/A, 5 10-Q, 2 DEF 14A, 2 10-K, 5 SC 13G/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (24)
Risk Profile
Risk Assessment: Of CYCN's 19 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 8 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$4.5M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $15.3M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Regina Graul
- Rhonda Chicko
- Mr. Amaury Wittouck
- Abigail P. Johnson
Industry Context
Cyclerion operates in the biopharmaceutical sector, a highly competitive and capital-intensive industry. Success hinges on drug discovery, development, and regulatory approval. The industry is characterized by significant R&D investment, long development cycles, and substantial risks associated with clinical trials and market adoption. Companies often rely on strategic partnerships, licensing agreements, and external funding to advance their pipelines.
Top Tags
10-Q (4) · sec-filing (3) · 8-k (3) · SEC Filing (3) · financials (3) · material-agreement (3) · Cyclerion Therapeutics (3) · institutional-ownership (3) · amendment (3) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenues | $2.0M | Increased from $0 in 2023, driven by license and option revenues. |
| Net Loss | $3.057M | Improved from $5.263M in 2023, but still a significant loss. |
| Other Investment | $5.4M | Investment in Tisento Therapeutics Holdings Inc., subject to Critical Audit Matter. |
| Cash and Cash Equivalents | $3.232M | Decreased from $7.571M in 2023, indicating declining liquidity. |
| Total Assets | $9.575M | Decreased from $13.374M in 2023, reflecting overall asset reduction. |
| Research and Development Costs | $0.286M | Significant reduction from $1.515M in 2023. |
| General and Administrative Costs | $5.342M | Reduced from $8.132M in 2023. |
| Market Value of Non-Affiliate Common Stock | $4.8M | As of June 30, 2024, indicating a small market capitalization. |
| Shares of Common Stock Outstanding | 2,710,096 | As of February 28, 2025. |
| Net Loss Per Share | $1.21 | For the year ended December 31, 2024, improved from $2.25 in 2023. |
| SEC File Number | 001-38787 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 83-1895370 | Tax identification number for the company. |
| Revenue | $0 | No revenue for Q2 2025 or H1 2025, consistent with prior periods. |
| Net Loss (Q2 2025) | -$4.5M | Improved from -$10.2M in Q2 2024, a 55.8% reduction. |
| Net Loss (H1 2025) | -$9.8M | Improved from -$20.5M in H1 2024, a 52.2% reduction. |
Forward-Looking Statements
- {"claim":"FMR LLC will likely maintain a significant, but passive, stake in Cyclerion Therapeutics, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cyclerion Therapeutics, Inc. (CYCN)?
Cyclerion Therapeutics, Inc. has 24 recent SEC filings from Jan 2024 to Dec 2025, including 9 8-K, 5 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CYCN filings?
Across 24 filings, the sentiment breakdown is: 2 bearish, 22 neutral. The dominant sentiment is neutral.
Where can I find Cyclerion Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cyclerion Therapeutics, Inc. (CYCN) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cyclerion Therapeutics, Inc.?
Key financial highlights from Cyclerion Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CYCN?
The investment thesis for CYCN includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cyclerion Therapeutics, Inc.?
Key executives identified across Cyclerion Therapeutics, Inc.'s filings include Regina Graul, Rhonda Chicko, Mr. Amaury Wittouck, Abigail P. Johnson.
What are the main risk factors for Cyclerion Therapeutics, Inc. stock?
Of CYCN's 19 assessed filings, 2 were flagged high-risk, 9 medium-risk, and 8 low-risk.
What are recent predictions and forward guidance from Cyclerion Therapeutics, Inc.?
Recent forward-looking statements from Cyclerion Therapeutics, Inc. include guidance on {"claim":"FMR LLC will likely maintain a significant, but passive, stake in Cyclerion Therapeutics, Inc. for the foresee.